{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:33:39Z","timestamp":1769070819926,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.4158\/ep161713.or","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T11:32:12Z","timestamp":1490268732000},"page":"662-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pentraxin 3 as a New Cardiovascular Marker in Adrenal Adenomas"],"prefix":"10.1016","volume":"23","author":[{"given":"Muhammed","family":"Kizilgul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selvihan","family":"Beysel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgur","family":"Ozcelik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyfullah","family":"Kan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"Apaydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bekir","family":"Ucan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkam","family":"Sencar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyda","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erman","family":"Cakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP161713.OR_bb0010","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1582-4934.2007.00061.x","article-title":"Role of the soluble pattern recognition receptor PTX3 in vascular biology","volume":"11","author":"Presta","year":"2007","journal-title":"J Cell Mol Med"},{"key":"10.4158\/EP161713.OR_bb0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1189\/jlb.1005557","article-title":"The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility","volume":"79","author":"Bottazzi","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.4158\/EP161713.OR_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08916934.2011.611549","article-title":"Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications","volume":"45","author":"Cie\u015blik","year":"2012","journal-title":"Autoimmunity"},{"key":"10.4158\/EP161713.OR_bb0025","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1161\/01.CIR.0000145167.30987.2E","article-title":"Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction","volume":"110","author":"Latini","year":"2004","journal-title":"Circulation"},{"key":"10.4158\/EP161713.OR_bb0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2010.10.018","article-title":"Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction","volume":"57","author":"Matsubara","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP161713.OR_bb0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/acr.20094","article-title":"Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with the inflammatory rheumatic disease","volume":"62","author":"Hollan","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.4158\/EP161713.OR_bb0040","first-page":"588","article-title":"Comparative diagnostic accuracy of serum levels of neutrophil activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome","volume":"11","author":"Ust\u00fcnda\u011f","year":"2011","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.4158\/EP161713.OR_bb0045","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP161713.OR_bb0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"key":"10.4158\/EP161713.OR_bb0055","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/HJH.0b013e32834a4ce9","article-title":"Cardiovascular manifestations of phaeochromocytoma","volume":"29","author":"Prejbisz","year":"2011","journal-title":"J Hypertens"},{"key":"10.4158\/EP161713.OR_bb0060","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2213-8587(13)70211-0","article-title":"Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study","volume":"2","author":"Di Dalmazi","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP161713.OR_bb0065","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1148\/radiographics.21.4.g01jl21995","article-title":"State-of-the-art adrenal imaging","volume":"21","author":"Mayo-Smith","year":"2001","journal-title":"Radiographics"},{"key":"10.4158\/EP161713.OR_bb0070","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"10.4158\/EP161713.OR_bb0075","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","article-title":"High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of heart disease","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation"},{"key":"10.4158\/EP161713.OR_bb0080","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000336589","article-title":"Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas","volume":"21","author":"Yener","year":"2012","journal-title":"Med Princ Pract"},{"key":"10.4158\/EP161713.OR_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tcm.2010.03.005","article-title":"The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases","volume":"20","author":"Norata","year":"2010","journal-title":"Trends Cardiovasc Med"},{"key":"10.4158\/EP161713.OR_bb0090","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1161\/01.CIR.0000145167.30987.2E","article-title":"Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction","volume":"110","author":"Latini","year":"2004","journal-title":"Circulation"},{"key":"10.4158\/EP161713.OR_bb0095","doi-asserted-by":"crossref","first-page":"725102","DOI":"10.1155\/2013\/725102","article-title":"Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases","volume":"2013","author":"Bonacina","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.4158\/EP161713.OR_bb0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/path.2314","article-title":"Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions","volume":"215","author":"Savchenko","year":"2008","journal-title":"J Pathol"},{"key":"10.4158\/EP161713.OR_bb0105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5551\/jat.No613","article-title":"Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia","volume":"16","author":"Ohbayashi","year":"2009","journal-title":"J Atheroscler Thromb"},{"key":"10.4158\/EP161713.OR_bb0110","doi-asserted-by":"crossref","first-page":"e100045","DOI":"10.1371\/journal.pone.0100045","article-title":"Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability","volume":"9","author":"Shindo","year":"2014","journal-title":"PLoS One"},{"key":"10.4158\/EP161713.OR_bb0115","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/j.1582-4934.2009.00855.x","article-title":"Fibroblast growth factor 2-antagonist activity of a long pentraxin 3-derived anti-angiogenic pentapeptide","volume":"14","author":"Leali","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.4158\/EP161713.OR_bb0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2003-10-3433","article-title":"Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis","volume":"104","author":"Rusnati","year":"2004","journal-title":"Blood"},{"key":"10.4158\/EP161713.OR_bb0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1536\/ihj.13-253","article-title":"Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein","volume":"55","author":"Yasunaga","year":"2014","journal-title":"Int Heart J"},{"key":"10.4158\/EP161713.OR_bb0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF03347083","article-title":"Is there an association between non-functioning adrenal adenoma and endothelial dysfunction?","volume":"34","author":"Yener","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP161713.OR_bb0135","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1161\/01.ATV.0000015595.95497.2F","article-title":"Production of the long pentraxin PTX3 in advanced atherosclerotic plaques","volume":"22","author":"Rolph","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.4158\/EP161713.OR_bb0140","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s002689900441","article-title":"Can adrenal incidentalomas be safely observed?","volume":"22","author":"Barry","year":"1998","journal-title":"World J Surg"},{"key":"10.4158\/EP161713.OR_bb0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s002689910095","article-title":"Natural course of adrenal incidentalomas: seven-year follow-up study","volume":"24","author":"Sir\u00e9n","year":"2000","journal-title":"World J Surg"},{"key":"10.4158\/EP161713.OR_bb0150","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1210\/jc.2013-4064","article-title":"Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion","volume":"99","author":"Androulakis","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161713.OR_bb0155","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1210\/jc.2009-1588","article-title":"Hypertrophic remodeling of subcutaneous small resistance arteries in patients with Cushing's syndrome","volume":"94","author":"Rizzoni","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161713.OR_bb0160","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","article-title":"Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction","volume":"54","author":"Mihailidou","year":"2009","journal-title":"Hypertension"},{"key":"10.4158\/EP161713.OR_bb0165","doi-asserted-by":"crossref","first-page":"991","DOI":"10.12659\/MSM.897714","article-title":"Carotid intima-media thickness as the cardiometabolic risk indicator in patients with nonfunctional adrenal mass and metabolic syndrome screening","volume":"22","author":"Evran","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.4158\/EP161713.OR_bb0170","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40618-014-0106-5","article-title":"Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and an increased risk of atherosclerosis","volume":"37","author":"Tuna","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP161713.OR_bb0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.metabol.2006.12.018","article-title":"Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma","volume":"56","author":"Ermetici","year":"2007","journal-title":"Metabolism"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20358055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20358055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:02:59Z","timestamp":1761516179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20358055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1530891X20358055"],"URL":"https:\/\/doi.org\/10.4158\/ep161713.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pentraxin 3 as a New Cardiovascular Marker in Adrenal Adenomas","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP161713.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}